

Girijesh Kumar Patel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9412519/girijesh-kumar-patel-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

300
citations

6
h-index

10
g-index

10
ext. papers

417
ext. citations

5.8
avg, IF

3.38
L-index

#	Paper	IF	Citations
10	MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer. <i>British Journal of Cancer</i> , 2021 ,	8.7	1
9	The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens. <i>Pharmacogenomics Journal</i> , 2021 , 21, 308-317	3.5	0
8	-Induced Inflammation: Possible Factors Modulating the Risk of Gastric Cancer. <i>Pathogens</i> , 2021 , 10,	4.5	3
7	Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. <i>Journal of Biological Chemistry</i> , 2020 , 295, 8413-8424	5.4	18
6	Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. <i>Cancers</i> , 2019 , 11,	6.6	34
5	The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e280-e286	3.8	6
4	Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 416-424	2.8	11
3	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. <i>British Journal of Cancer</i> , 2017 , 116, 609-619	8.7	159
2	Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	42
1	Glucose Metabolism Reprogrammed by Overexpression of IKK Promotes Pancreatic Tumor Growth. <i>Cancer Research</i> , 2016 , 76, 7254-7264	10.1	26